IBOGAINE Act
committeeSign in to watch / set alerts
TQL analysis
D62
62 / 90 · methodology full_text_v3
The IBOGAINE Act aims to accelerate the development and access to psychedelic drugs for treating serious mental illnesses. It establishes a voucher program for priority review of certain drugs, amends the right to try law, and revises DEA quota requirements. The bill also promotes federal-state collaboration and interagency partnerships with the private sector.
Legislative structure
Criterion breakdown8 criteria · max 90
Advanced Full criterion breakdown
The letter, score, and explanation above are free. The point-by-point breakdown of all eight scored criteria — with each criterion's value and how it moved the grade — is a Quiet Ledger research capability.
Access options →Actions (4)
| Date | Time | Action |
|---|---|---|
| 2026-06-30 | — | Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
| 2026-06-30 | — | Introduced in House |
| 2026-06-30 | — | Introduced in House |
| 2026-07-17 | — | Referred to the Subcommittee on Health. |
Provenance
- Methodology
- full_text_v3
- Calculated
- 2026-09-18 17:03:43.264+00
- Source version
- 2026-07-17
- Assessments
- —
The Quiet Ledger grades legislation on its content. A bill grade is analysis of the bill — not a grade of its sponsor or of any member who voted on it.